RxDoctor Payments Data

Susan Goodman, MD

Rheumatology · New York, NYNPI 1790748812

Payments from drug & device makers

$129,363in general payments, 2019–2025

Across 17 payments — averaging $7609.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$114K
  • UCB SA$12K
  • Johnson & Johnson$2K
  • Pfizer$370
  • Merck$111
  • Amgen$49

What the payments were for

  • Consulting fees$14,89298%
  • Food & beverage$3102%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis2$114,161
UCB SA8$12,362
Johnson & Johnson2$2,310
Pfizer1$370
Merck2$111
Amgen2$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,363 in reported general payments places this provider in the 85th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$128,205
Medicare patients
361
Services billed
3,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf)Adalimumab61$488,285
Enbrel SureclickEtanercept51$417,301
Humira(Cf) PenAdalimumab39$371,111
Cosentyx Sensoready (2 Pens)Secukinumab25$338,092
OtezlaApremilast52$258,349
XeljanzTofacitinib Citrate28$206,046
Taltz AutoinjectorIxekizumab23$178,128
HumiraAdalimumab23$147,378
ActemraTocilizumab25$141,783
RinvoqUpadacitinib15$93,078
EnbrelEtanercept13$90,984
Cimzia (2 Pack)Certolizumab Pegol12$67,528
OrenciaAbatacept11$65,836
RasuvoMethotrexate/Pf40$24,640
MethotrexateMethotrexate Sodium464$15,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla, Enbrel$49$349,33265 claims
PfizerXeljanz$370$206,04628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 541 rheumatology providers in New York.

Other rheumatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →